Anticipate heightened investor interest and potential stock movement around May 21–June 2 as data is released and presented. Monitor for response rates, durability, and safety signals in the upcoming disclosures, which could influence near-term valuation. This ASCO cycle may serve as a key inflection point for Immatics’ PRAME and MAGEA programs.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $11.18entry
- T+1 · 7mo ago +0.72%α −0.30% · $11.26
- T+5 · 7mo ago +3.67%α +2.58% · $11.59
- T+20 · 6mo ago −5.01%α −9.92% · $10.62
- T+60 · 4mo ago −15.92%α −22.82% · $9.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 ASCO Annual Meeting, featuring clinical data from its PRAME-targeted cell therapies (anzu-cel, IMA203CD8) and MAGEA4/8 bispecific (IMA401) across multiple solid tumors. The presentations include updated Phase 1b and Phase 1a/1b data in melanoma, gynecologic cancers, synovial sarcoma, and first-in-human results for IMA401. This visibility at a top oncology conference highlights clinical progress in its core pipeline programs.
Key Facts
- Four abstracts accepted for oral presentation at ASCO 2026, a high-impact oncology conference
- Data includes updated Phase 1b results for anzu-cel in advanced melanoma and Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- First-in-human results for IMA401, a MAGEA4/8 bispecific, to be presented across multiple solid tumors
- Presentations span melanoma, gynecologic cancers, and synovial sarcoma, demonstrating broad applicability of PRAME-targeted therapies
- Full data to be released May 21, 2026, ahead of live presentations from May 30–June 2
Financial Impact
Non-financial but high strategic value; potential to drive partnership interest and investor confidence
Risk Factors
- Data remains preliminary and subject to change after final verification
- Oral presentation does not guarantee positive or clinically meaningful results
- Market may react negatively if data shows limited efficacy or safety concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278156 |
Track record
23 reports on IMTX
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers